This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Onyx Sells Japan Rights to Blood Cancer Drug

Stocks in this article: ONXXCELG

EMERYVILLE, Calif. ( TheStreet) -- Onyx Pharmaceuticals (ONXX) has sold Japanese rights to its multiple myeloma drug candidate carfilzomib to the Japanese drug maker Ono Pharmaceuticals, the company announced Wednesday.

Ono will pay Onyx $59 million upfront in exchange for Japanese development and marketing rights to carfilzomib plus a follow-on compound known as ONX 0912. Onyx is also eligible to receive future milestone payments that could bring in another $280 million. If carfilzomib or ONX 0912 is approved for sale in Japan, Ono will pay Onyx double-digit royalties on drug sales, according to terms of the agreement released by Onyx.

The Ono deal helps Onyx recoup some of the $275 million it paid for carfilzomib through the acquisition of privately held Proteolix in October 2009.

Onyx CEO Tony Coles says Onyx intends to retain U.S. and western Europe rights to carfilzomib but will look for other partnerships to cover the rest of Asia.

Coles says the multiple myeloma market in Japan is estimated to be worth an estimated $80 million to $100 million today but is growing. Celgene (CELG) recently received approval from Japanese drug regulators to sell its multiple myeloma drug Revlimid there.

Carfilzomib is a next generation proteasome inhibitor designed to be as potent and cause less side effects than a similar drug, Velcade, sold by Takeda Pharmaceuticals.

Onyx intends to seek U.S. regulatory approval for carfilzomib by the end of the year. The initial filing will be for an accelerated approval based on a phase II study of carfilzomib which demonstrated a 24% response rate and more than 7 months duration of response in patients whose multiple myeloma continued to progress despite previous treatments with Celgene's Revlimid and Takeda's Velcade.

FDA's recent refusal to consider a Roche breast cancer drug for accelerated approval has investors concerned about the agency's possibly raising the bar for the accelerated approval of cancer drugs.

Onyx's Coles says he's fielded investor questions about carfilzomib and FDA accelerated approval about 14 dozen times in the past two weeks since FDA dinged Roche.

"I can't guarantee FDA approval, the FDA will do what it wants to do, but I do believe that the carfilzomib data demonstrate the drug is providing a significant response to patients in which all other currently approved drugs have failed," he says.

Onyx is expected to present a full dataset from the carfilozmib phase II study at the American Society of Hematology annual meeting in December.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs